Akari Total Debt To Capitalization from 2010 to 2025

AKTX Stock  USD 1.27  0.03  2.31%   
Akari Therapeutics Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization is likely to outpace its year average in 2025. During the period from 2010 to 2025, Akari Therapeutics Total Debt To Capitalization regression line of annual values had significance of  0 and arithmetic mean of (0.07). View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.000099
Current Value
0.000104
Quarterly Volatility
0.14707404
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Akari Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akari Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 6.4 M, Selling General Administrative of 7.6 M or Other Operating Expenses of 18 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Akari financial statements analysis is a perfect complement when working with Akari Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Akari Therapeutics Correlation against competitors.

Latest Akari Therapeutics' Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Akari Therapeutics PLC over the last few years. It is Akari Therapeutics' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akari Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Slightly volatile
   Total Debt To Capitalization   
       Timeline  

Akari Total Debt To Capitalization Regression Statistics

Arithmetic Mean(0.07)
Coefficient Of Variation(215.31)
Mean Deviation0.11
Median0.0001
Standard Deviation0.15
Sample Variance0.02
Range0.3649
R-Value0.68
Mean Square Error0.01
R-Squared0.46
Significance0
Slope0.02
Total Sum of Squares0.32

Akari Total Debt To Capitalization History

2025 1.04E-4
2024 9.9E-5
2014 1.1E-4
2013 1.9E-5

About Akari Therapeutics Financial Statements

Akari Therapeutics investors use historical fundamental indicators, such as Akari Therapeutics' Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Akari Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.